Time filter

Source Type

Chen X.,Soochow University of China | Sun M.,General Hospital of PLA Second Artillery | Hu Y.,Institute of Geriatrics | Zhang H.,Institute of Geriatrics | And 3 more authors.
Oncology Letters

Members of the FXYD domain-containing ion transport regulator protein family, including FXYD3 and FXYD5, play an important role in the pathogenesis of numerous tumors. However, the correlation between the expression of FXYD6 and tumors remains poorly understood. In the current study, the expression of FXYD6 was examined immunohistochemically in 72 cholangiocarcinoma tissues and 30 distal normal bile duct tissues matched with the tumors. The results show that the positive expression rate of FXYD6 was significantly higher in cholangiocarcinoma than that in normal bile duct tissue (69 vs. 33.3%; P=0.002). Furthermore, the positive expression rate of FXYD6 in well- and moderately-differentiated cholangiocarcinoma was clearly higher than that in poorly-differentiated and mucinous cholangiocarcinoma (85.7 vs. 40%; P=0.000). However, there was no significant correlation between the expression of FXYD6 and gender (P=0.393), age (P=0.174), histological type (P=0.123), T stage (P=0.164), lymph node metastasis (P=0.343), perineural invasion (P=0.088) and tumor location (P=0.238). The results of this study indicate that FXYD6 may be a new biomarker for cholangiocarcinoma and may be associated with a favorable prognosis in this malignant disease. Source

Gao Q.,University of Chinese Academy of Sciences | Chen X.,Soochow University of China | Duan H.,University of Chinese Academy of Sciences | Wang Z.,University of Chinese Academy of Sciences | And 5 more authors.
Protein and Cell

FXYD6, FXYD domain containing ion transport regulator 6, has been reported to affect the activity of Na+/K+-ATPase and be associated with mental diseases. Here, we demonstrate that FXYD6 is up-regulated in hepatocellular carcinoma (HCC) and enhances the migration and proliferation of HCC cells. Up-regulation of FXYD6 not only positively correlates with the increase of Na+/K+-ATPase but also coordinates with the activation of its downstream Src-ERK signaling pathway. More importantly, blocking FXYD6 by its functional antibody significantly inhibits the growth potential of the xenografted HCC tumors in mice, indicating that FXYD6 represents a potential therapeutic target toward HCC. Altogether, our results establish a critical role of FXYD6 in HCC progression and suggest that the therapy targeting FXYD6 can benefit the clinical treatment toward HCC patients. © 2014 The Author(s). Source

Zhu Z.,PLA NO. 302 Hospital | Liu Q.,Institute of Hepatobiliary Gastrointestinal Disease | Chen J.,Institute of Hepatobiliary Gastrointestinal Disease | Duan W.,Institute of Hepatobiliary Gastrointestinal Disease | And 7 more authors.
Surgical Laparoscopy, Endoscopy and Percutaneous Techniques

OBJECTIVE:: To explore and find a new method to treat hilar cholangiocarcinoma with deep jaundice assisted by Da Vinci robot. METHODS:: A hilar cholangiocarcinoma patient of type Bismuch-Corlette IIIa was found with deep jaundice (total bilirubin: 635 μmol/L). On the first admission, we performed Da Vinci robotic surgery including drainage of left hepatic duct, dissection of right hepatic vessels (right portal vein and right hepatic artery), and placement of right-hepatic vascular control device. Three weeks later on the second admission when the jaundice disappeared we occluded right-hepatic vascular discontinuously for 6 days and then sustained later. On the third admission after 3 weeks of right-hepatic vascular control, the right hemihepatectomy was performed by Da Vinci robot for the second time. RESULTS:: The future liver remnant after the right-hepatic vascular control increased from 35% to 47%. The volume of left lobe increased by 368 mL. When the total bilirubin and liver function were all normal, right hemihepatectomy was performed by Da Vinci robot 10 weeks after the first operation. The removal of atrophic right hepatic lobe with tumor in bile duct was found with no pathologic cancer remaining in the margin. The patient was followed up at our outpatient clinic every 3 months and no tumor recurrence occurs by now (1 y). CONCLUSIONS:: Under the Da Vinci robotic surgical system, a programmed treatment can be achieved: first, the hepatic vessels were controlled gradually together with biliary drainage, which results in liver's partial atrophy and compensatory hypertrophy in the other part. Then a radical hepatectomy could be achieved. Such programmed hepatectomy provides a new treatment for patients of hilar cholangiocarcinoma with deep jaundice who have the possibility of radical heptolobectomy. © 2014 by Lippincott Williams & Wilkins. Source

Liu Q.,Institute of Hepatobiliary Gastrointestinal Disease | Zhou N.,Institute of Hepatobiliary Gastrointestinal Disease | Xu X.,Institute of Hepatobiliary Gastrointestinal Disease | Wang Z.,Institute of Hepatobiliary Gastrointestinal Disease
Journal of Gastrointestinal and Liver Diseases

Radiofrequency ablation (RFA) for treatment of splenic tumors has rarely been reported. Here we describe our experiences of undergoing RFA in three patients with solitary metastatic (n=2) and benign (n=1) tumors of the spleen. Two patients also had underlying cirrhotic hypersplenism. A 53-year-old male with solitary splenic metastasis from hepatocellular carcinoma underwent laparoscopical RFA of the splenic tumor. Another 61-year-old female with intraabdominal recurrence, focal splenic metastasis from colon cancer and cirrhotic hypersplenism underwent cytoreductive surgery and RFA of splenic tumors. On the third patient, a 32-year-old man with severe hypersplenism, splenic artery steal syndrome and a solitary splenic hemangioma, a laparoscopical RFA of the splenic tumor was performed. The three patients recovered uneventfully. The concurrent hypersplenism of the latter two patients improved significantly The results indicate that RFA of splenic tumors is feasible and safe, and could be evaluated as an alternative to splenectomy in selected patients with solitary splenic tumors. Source

Liu Q.-D.,Institute of Hepatobiliary Gastrointestinal Disease | Chen J.-Z.,Institute of Hepatobiliary Gastrointestinal Disease | Xu X.-Y.,Institute of Hepatobiliary Gastrointestinal Disease | Zhang T.,Institute of Hepatobiliary Gastrointestinal Disease | Zhou N.-X.,Institute of Hepatobiliary Gastrointestinal Disease
World Journal of Gastroenterology

AIM: To investigate the incidence of clinically detected port-site metastasis (PSM) in patients who underwent robotic surgery for biliary malignancies. METHODS: Using a prospective database, the patients undergoing fully robotic surgery for biliary malignancies between January 2009 and January 2011 were included. Records of patients with confirmed malignancy were reviewed for clinicopathological data and information about PSM. RESULTS: Sixty-four patients with biliary tract cancers underwent robotic surgery, and sixty patients met the inclusion criteria. The median age was 67 year (range: 40-85 year). During a median 15-mo follow-up period, two female patients were detected solitary PSM after robotic surgery. The incidence of PSM was 3.3%. Patient 1 underwent robotic anatomatic left hemihepatectomy and extraction of biliary tumor thrombi for an Klatskin tumor. She had a subcutaneous mass located at the right lateral abdominal wall near a trocar scar. Patient 2 underwent robotic pancreaticoduodenectomy for distal biliary cancer. She had two metachronous subcutaneous mass situated at the right lateral abdominal wall under a same trocar scar at 7 and 26 mo. The pathology of the excised PSM masses confirmed metastatic biliary adenocarcinoma. CONCLUSION: The incidence of PSMs after robotic surgery for biliary malignancies is relatively low, and biliary cancer can be an indication of robotic surgery. © 2012 Baishideng. All rights reserved. Source

Discover hidden collaborations